There’s limited knowledge about the potential value of marine growth on decommissioned offshore assets. CessCon Decom wanted to characterise the nutritional composition of the marine growth and assess the feasibility of extracting valuable components.

This project aimed to address two distinct issues; costly waste from salmon fisheries and the toxicity and unsustainability of conventional surfactants, which are produced from synthetic or petrochemical feedstocks.

This Feasibility Fund project explored the use of oil extracted from fish industry waste to create an eco-friendly, high-value, biobased surfactants, an innovative approach that could ensure affordability and align with sustainable practices.

This project assessed the effect of growth media formulation and time of harvest on the growth rate, biochemical composition, and digestibility of a selection of phytoplankton maintained at CCAP, and identified two strains of commercial interest.

The Antibody Company (TAC) has expertise in point of care diagnostics for the aquaculture and brewing industries, which both suffer significant product losses. Current diagnostics for these industries are prohibitively expensive and take too long allow immediate mitigation. TAC combined their expertise in antibody design and production with Dr. Mulheran and his team’s skills in antibody conjugation to design a cheap and effective lateral flow device (LFD).

ŌGI Bio Ltd wanted to explore the feasibility of utilising the University of Edinburgh’s state of the art in-line dilution technology to extend the valid range of OD measurements for their microbioreactors.

Turning low value fish waste into high value molecules using biotechnology.

This project investigated the feasibility of using oils extracted from fish industry waste to produce ingredients such as detergents and foaming agents for use in industrial products.

New technology may help reduce carbon emissions for the agriculture and aquaculture industries.

MiAlgae successfully carried out early stage bioprocess development work within IBioIC's bioprocessing facilities in Glasgow and Edinburgh.